eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
4/2017
vol. 12
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł przeglądowy

The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease

Anita Gąsiorowska

Data publikacji online: 2017/12/14
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 


Gastroesophageal reflux disease (GERD) is a condition in which gastroduodenal contents pass into the oesophagus and cause troublesome symptoms and complications. The aetiopathogenesis of gastroesophageal reflux disease is complex and multifactorial. Acid reflux plays an important role in the GERD pathogenesis, both in erosive and non-erosive reflux disease. Reduction of GERD symptoms and mucosal healing correlates with the number of hours that intragastric acid is suppressed to a pH > 4.0. Mucosal healing was achieved in most of patients who received different types of proton pump inhibitors, but only in 50% of those who received H2 blockers. These findings seem to be best accounted for by differences in the duration and degree of acid suppression achieved by different classes of drugs and perhaps between agents within those classes.
referencje:
El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80.
Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence based consensus. Am J Gastroenterol 2006; 101: 1900-20.
Castell DO, Murray JA, Tutuian R, et al. Review article: the pathophysiology of gastro-oesophageal reflux disease – oesophageal manifestations. Aliment Pharmacol Ther 2004; 20: 14-25.
Kahrilas P, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392-413.
Coron E, Hatlebakk JG, Galmiche JP, et al. Medical therapy of gastro­esophageal reflux disease. Curr Opin Gastroenterol 2007; 23: 434-9.
DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155: 2165-73.
Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol 2009; 15: 990-5.
Eggleston A, Katelaris PH, Nandurkar S, et al. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care – prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009; 29: 967-78.
Calvet X, Gomollon F. What is potent acid inhibition, and how can it be achieved? Drugs 2005; 65: (Suppl 1): 13-23.
Hatlebakk JG. Review article: gastric acidity – comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 2003; 17 (Suppl 1): 10-5.
Dean BB, Gano AD, Knight K, et al. Effectiveness of proton pump inhibitors in non-erosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85.
Leite LP, Johnston BT, Just RJ, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527-31.
Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2014; 5: 105-12.
Subramanian CR, Triadafilopoulos G. Refractory gastroesophageal reflux disease. Gastroenterol Rep 2015; 3: 41-53.
Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesopahgeal reflux disease. Aliment Pharmacol Ther 2005; 22: 129-34.
Metz DC, Vakily M, Dixit T, et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 29: 928-37.
Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med 2011; 43: 366-74.
Lee RD, Vakily M, Mulford D, et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility. Aliment Pharmacol Ther 2009; 29: 824-33.
Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther 2010; 31: 1001-11.
Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol 2011; 4: 213-20.
Zhang W, Wu J, Atkinson SN. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology 2007; 132 (suppl 52): A487.
Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51 Suppl 1: 59-67.
Wu J, Vakily M, Witt G, et al. TAK-390 MR vs. Lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol 2007; 102 (Suppl 2): 124.
Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studies. Aliment Pharmacol Ther 2009; 29: 731-41.
Fass R. Effect of gastroesophageal reflux disease on sleep. J Gastroenterol Hepatol 2010; 25 Suppl 1: S41-4.
Pasricha PJ. Effect of sleep on gastroesophageal physiology and airway protective mechanisms. Am J Med 2003; 115: 114S-8S.
Orr WC. Reflux events and sleep: are we vulnerable? Curr Gastroenterol Rep 2006; 8: 202-7.
Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment Pharmacol Ther 2005; 21: 963-7.
Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 658-64.
Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011; 106: 421-31.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe